These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31020542)

  • 1. Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma.
    Wang Y; Zhang J; Wang Y; Wang S; Zhang Y; Miao Q; Gao F; He H
    Front Med; 2019 Dec; 13(6):730-740. PubMed ID: 31020542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study.
    Calandrella ML; Francesconi S; Caprera C; Mosillo C; Caserta C; Giannarelli D; Corsi M; Macrini S; Guida A; Ascani S; Bracarda S
    BMC Cancer; 2022 Feb; 22(1):168. PubMed ID: 35164713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications.
    Schneider B; Glass Ä; Jagdmann S; Hühns M; Claus J; Zettl H; Dräger DL; Maruschke M; Hakenberg OW; Erbersdobler A; Zimpfer A
    Clin Genitourin Cancer; 2020 Oct; 18(5):e563-e572. PubMed ID: 32340874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
    Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular aspects of upper tract urothelial carcinoma.
    Patel N; Arya M; Muneer A; Powles T; Sullivan M; Hines J; Kelly J
    Urol Oncol; 2014 Jan; 32(1):28.e11-20. PubMed ID: 23428541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
    Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
    Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract].
    Burger M; Catto J; van Oers J; Zwarthoff E; Hamdy FC; Meuth M; Azzouri AR; Cussenot O; Wild PJ; Stoehr R; Hartmann A
    Verh Dtsch Ges Pathol; 2006; 90():244-52. PubMed ID: 17867603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
    Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ
    Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
    Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
    Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of GATA3/FOXA1 co-expression predicts poor prognosis in upper tract urothelial carcinoma.
    Wang Y; Wang Y; He H; Xiong Y
    Front Oncol; 2024; 14():1302864. PubMed ID: 38425344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion.
    Kosaka T; Kikuchi E; Mikami S; Miyajima A; Shirotake S; Ishida M; Okada Y; Oya M
    Clin Cancer Res; 2010 Dec; 16(23):5814-23. PubMed ID: 20947514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy.
    Shibing Y; Turun S; Qiang W; Junhao L; Haichao Y; Shengqiang Q; Ping H; Dehong C
    Urol Oncol; 2015 May; 33(5):204.e9-16. PubMed ID: 25800374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma.
    Youssef RF; Krabbe LM; Shariat SF; Lotan Y; Sagalowsky AI; Raman J; Wood CG; Weizer A; Roscigno M; Montorsi F; Bolenz C; Remzi M; Bensalah K; Kassouf W; Margulis V
    World J Urol; 2015 Dec; 33(12):1965-72. PubMed ID: 25957592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis.
    Blaszyk H; Wang L; Dietmaier W; Hofstädter F; Burgart LJ; Cheville JC; Hartmann A
    Mod Pathol; 2002 Aug; 15(8):790-7. PubMed ID: 12181263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
    Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.
    Wang X; Lopez-Beltran A; Osunkoya AO; Wang M; Zhang S; Davidson DD; Emerson RE; Williamson SR; Tan PH; Kaimakliotis HZ; Baldridge LA; MacLennan GT; Montironi R; Cheng L
    Future Oncol; 2017 Apr; 13(8):705-714. PubMed ID: 28052688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
    Ruemmele P; Dietmaier W; Terracciano L; Tornillo L; Bataille F; Kaiser A; Wuensch PH; Heinmoeller E; Homayounfar K; Luettges J; Kloeppel G; Sessa F; Edmonston TB; Schneider-Stock R; Klinkhammer-Schalke M; Pauer A; Schick S; Hofstaedter F; Baumhoer D; Hartmann A
    Am J Surg Pathol; 2009 May; 33(5):691-704. PubMed ID: 19252434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.